Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | BCL9 | O00512 | 1/20 | 0.58 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980348 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL26976962 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL10685191 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL21433889 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL21433828 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL2234364 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL9846659 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL21433779 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL21777065 | 0.99 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT | |
| SCHEMBL1144551 | 0.97 | MGLL (0.62) | MGLLBCL9CTNNB1HTR2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011067588-A1 | CYCLIC SULPHINYL ESTERS OF CYTIDINE | GENERICS [UK] LIMITED (GB) | 2011-06-09 | — | — | WO | claimed |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| WO-2024259930-A9 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2024259930-A1 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-117285566-A | Phosphonate compound and medical application thereof | 润佳（苏州）医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112442011-B | Prodrug compound and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4021912-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| CN-112442011-A | Prodrug compound and application thereof in treating cancer | 润佳（苏州）医药科技有限公司 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021035360-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-04 | — | — | WO | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767526-A1 | NOVEL ARYLAMIDINE DERIVATIVE, SALT THEREOF, AND ANTIFUNGAL CONTAINING THESE | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1383731-A4 | BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS | BIOCRYST PHARM INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6936719-B2 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | BIOCRYST PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-6699994-B1 | ANTICOAGULANTS; INHIBITORS OF THROMBIN, BLOOD COAGULATION FACTORS VIIA, XA, FVIIA, TISSUE FACTOR, AND TRYPSIN | BIOCRYST PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| EP-1383731-A1 | BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| WO-2002034711-A1 | BIARYL COMPOUNDS AS SERINE PROTEASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | MGLL 2065/4885BCL9 849/4885CTNNB1 3582/4885 |
| US-20040162281-A1 | Biaryl compounds as serine protease inhibitors | TFPI, SPINT2, TFPI2 | MGLL 730/4885BCL9 1884/4885CTNNB1 2972/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | MGLL 2427/4885BCL9 361/4885CTNNB1 1180/4885 |
| US-20080319016-A1 | Novel Arylamidine Derivative, Salt Thereof, and Antifungal Containing These | NAT1, ERG28, SLC7A1 | MGLL 4060/4885BCL9 2727/4885CTNNB1 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.